Table 4.
Rate of office blood pressure (BP) responders (<140/90 mmHg in nondiabetics and <130/80 mmHg in diabetics or high-risk patients, or SBP reduction ≥20 mmHg or DBP reduction ≥10 mmHg) and baseline-adjusted office and 24-hour SBP and DBP reductions after 48 weeks of treatment with zofenopril 60 mg + hydrochlorothiazide (HCTZ) or irbesartan 300 mg + HCTZ. Data are shown for the intention-to-treat population and reported as absolute (n) and relative (%) frequencies and as mean and 95% confidence interval. The p value refers to the statistical significance of the intertreatment difference.
| Zofenopril 60 mg + HCTZ 12.5 mg | Irbesartan 300 mg + HCTZ 12.5 mg | p value | |
|---|---|---|---|
| Office BP responders (n, %) | n = 119 | n = 104 | |
| 34 (28.6) | 23 (22.1) | 0.178 | |
| Office BP reduction with treatment | n = 119 | n = 104 | |
| SBP (mmHg) | 17.8 (15.6, 20.0) | 21.2 (18.6, 23.8) | 0.052 |
| DBP (mmHg) | 11.7 (10.3, 13.1) | 12.9 (11.3, 14.5) | 0.268 |
| 24-hour BP reduction with treatment | n = 50 | n = 44 | |
| SBP (mmHg) | 7.6 (9.7, 5.6) | 7.2 (9.3, 5.1) | 0.744 |
| DBP (mmHg) | 4.5 (6.1, 2.8) | 5.9 (7.5, 4.2) | 0.250 |